CA2553769A1 - Npc1l1 (npc3) and methods of identifying ligands thereof - Google Patents
Npc1l1 (npc3) and methods of identifying ligands thereof Download PDFInfo
- Publication number
- CA2553769A1 CA2553769A1 CA002553769A CA2553769A CA2553769A1 CA 2553769 A1 CA2553769 A1 CA 2553769A1 CA 002553769 A CA002553769 A CA 002553769A CA 2553769 A CA2553769 A CA 2553769A CA 2553769 A1 CA2553769 A1 CA 2553769A1
- Authority
- CA
- Canada
- Prior art keywords
- azetidinone
- glucuronide
- substituted
- value
- npc1l1
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/60—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving cholesterol
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5076—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving cell organelles, e.g. Golgi complex, endoplasmic reticulum
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
Abstract
The present invention provides human, rat and mouse NPCIL1 polypeptides and polynucleotides encoding the polypeptides. Methods for detecting ligands which bind to NPClL1 and block intestinal cholesterol absorption are provided. Also included is a method of identifying ligands which bind to NPCILI using membranes derived from brush border membrane preparations. Compounds that bind to NPCILI can be used for inhibiting intestinal cholesterol absorption in a subject.
Claims (20)
1. A method for identifying a ligand of NPC 1 L1 comprising:
contacting human NPC1L1 with a detectably labeled substituted 2-azetidinone glucuronide and a candidate compound; and determining whether said candidate compound binds to human NPC1L1;
wherein binding of said candidate compound to human NPC1L1 modulates binding of said detectably labeled substituted 2-azetidinone glucuronide to human NPC1L1, wherein the detectably labeled substituted 2-azetidinone glucuronide has a binding affinity KD value for human NPC1L1 that is 200nM or lower, and wherein said modulation indicates that the candidate compound is a ligand that binds to human NPC1L1.
contacting human NPC1L1 with a detectably labeled substituted 2-azetidinone glucuronide and a candidate compound; and determining whether said candidate compound binds to human NPC1L1;
wherein binding of said candidate compound to human NPC1L1 modulates binding of said detectably labeled substituted 2-azetidinone glucuronide to human NPC1L1, wherein the detectably labeled substituted 2-azetidinone glucuronide has a binding affinity KD value for human NPC1L1 that is 200nM or lower, and wherein said modulation indicates that the candidate compound is a ligand that binds to human NPC1L1.
2. The method of claim 1, wherein the KD value is 100nM or lower.
3. The method of claim 1, wherein the KD value is 50nM or lower.
4. The method of claim 1, wherein the KD value is 20nM or lower.
5. The method of claim 1, wherein the KD value is 10nM or lower.
6. The method of claim 1, wherein the substituted 2-azetidinone-glucuronide is selected from the group consisting of a compound of Formula I and a compound of Formula II.
7. The method of claim 6, wherein the substituted 2-azetidinone-glucuronide comprises a detectable label from the group consisting of 35S and 125I.
S. The method of claim 7, wherein the detectable label is 35S.
9. The method of claim 6, wherein the substituted 2-azetidinone-glucuronide is a compound of Formula II, wherein R9 comprises an -SO2- group.
10. The method of claim 9, wherein the substituted 2-azetidinone-glucuronide of Formula II is labeled with 35S.
11. A method for identifying a ligand of NPC1L1 comprising:
contacting human NPC1L1 with a detestably labeled substituted 2-azetidinone glucuronide of Formula II and a candidate compound; and determining whether said candidate compound binds to human NPC1L1;
wherein binding of said candidate compound to human NPC1L1 modulates binding of said detestably labeled substituted 2-azetidinone glucuronide of Formula II
to human NPC1L1, and wherein said modulation indicates that the candidate compound is a ligand that binds to human NPC1L1.
contacting human NPC1L1 with a detestably labeled substituted 2-azetidinone glucuronide of Formula II and a candidate compound; and determining whether said candidate compound binds to human NPC1L1;
wherein binding of said candidate compound to human NPC1L1 modulates binding of said detestably labeled substituted 2-azetidinone glucuronide of Formula II
to human NPC1L1, and wherein said modulation indicates that the candidate compound is a ligand that binds to human NPC1L1.
12. The method of claim 11, wherein R9 of the detestably labeled substituted 2-azetidinone glucuronide of Formula II comprises an -SO2- group.
13. The method of claim 11, wherein the detestably labeled substituted 2-azetidinone glucuronide of Formula II is labeled with 35S.
14. The method of claim 11, wherein the detestably labeled substituted 2-azetidinone glucuronide of Formula II has a binding affinity K D value for human NPC1L1 that is 200nM or lower.
15. The method of claim 14, wherein the K D value is 100nM or lower.
16. The method of claim 14, wherein the K D value is 50nM or lower.
17. The method of claim 14, wherein the K D value is 20nM or lower.
18. The method of claim 14, wherein the K D value is 10nM or lower.
19. The method of claim 1 wherein the detestably labeled substituted 2-azetidinone glucuronide is labeled with 35S.
20. The method of claim 1 wherein the detestably labeled substituted 2-azetidinone glucuronide is 35S-labeled compound 2.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US53734104P | 2004-01-16 | 2004-01-16 | |
US60/537,341 | 2004-01-16 | ||
PCT/US2005/001469 WO2005069900A2 (en) | 2004-01-16 | 2005-01-14 | Npc1l1 (npc3) and methods of identifying ligands thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2553769A1 true CA2553769A1 (en) | 2005-08-04 |
CA2553769C CA2553769C (en) | 2011-01-04 |
Family
ID=34807095
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA2553769A Expired - Fee Related CA2553769C (en) | 2004-01-16 | 2005-01-14 | Npc1l1 (npc3) and methods of identifying ligands thereof |
Country Status (6)
Country | Link |
---|---|
US (1) | US7901893B2 (en) |
EP (1) | EP1723414A4 (en) |
JP (1) | JP4590417B2 (en) |
CA (1) | CA2553769C (en) |
MX (1) | MXPA06008124A (en) |
WO (1) | WO2005069900A2 (en) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0215579D0 (en) | 2002-07-05 | 2002-08-14 | Astrazeneca Ab | Chemical compounds |
US7135556B2 (en) | 2002-07-19 | 2006-11-14 | Schering Corporation | NPC1L1 (NPC3) and methods of use thereof |
US20040132058A1 (en) * | 2002-07-19 | 2004-07-08 | Schering Corporation | NPC1L1 (NPC3) and methods of use thereof |
AU2004303742B2 (en) | 2003-12-23 | 2008-06-19 | Astrazeneca Ab | Diphenylazetidinone derivatives possessing cholesterol absorption inhibitory activity |
JP2007516287A (en) | 2003-12-23 | 2007-06-21 | メルク エンド カムパニー インコーポレーテッド | Anti-hypercholesterolemic compound |
EP1723414A4 (en) | 2004-01-16 | 2008-03-26 | Merck & Co Inc | Npc1l1 (npc3) and methods of identifying ligands thereof |
JP2008543837A (en) * | 2005-06-15 | 2008-12-04 | メルク エンド カムパニー インコーポレーテッド | Anti-hypercholesterolemic compound |
UY29607A1 (en) | 2005-06-20 | 2007-01-31 | Astrazeneca Ab | CHEMICAL COMPOUNDS |
AR057072A1 (en) | 2005-06-22 | 2007-11-14 | Astrazeneca Ab | CHEMICAL COMPOUNDS DERIVED FROM 2-AZETIDINONE, PHARMACEUTICAL FORMULATION AND A COMPOUND PREPARATION PROCESS |
SA06270191B1 (en) | 2005-06-22 | 2010-03-29 | استرازينيكا ايه بي | Novel 2-Azetidinone Derivatives as Cholesterol Absorption Inhibitors for the Treatment of Hyperlipidaemic Conditions |
DE102005055726A1 (en) * | 2005-11-23 | 2007-08-30 | Sanofi-Aventis Deutschland Gmbh | Hydroxy-substituted diphenylazetidinones, processes for their preparation, medicaments containing these compounds and their use |
EP1986489A2 (en) | 2006-02-24 | 2008-11-05 | Schering Corporation | Npc1l1 orthologues |
AR060623A1 (en) | 2006-04-27 | 2008-07-02 | Astrazeneca Ab | COMPOUNDS DERIVED FROM 2-AZETIDINONE AND A PREPARATION METHOD |
US20100184094A1 (en) * | 2007-06-28 | 2010-07-22 | Garcia Maria L | Use of mdck cells in the evaluation of cholesterol modulators |
CN101580871B (en) * | 2008-05-13 | 2013-06-05 | 中国科学院上海生命科学研究院 | Method for screening new drug for lowering cholesterol based on analysis of change of NPC1L1 protein subcellular localization |
EP2581094A4 (en) * | 2010-06-10 | 2015-04-08 | Adbiotech Co Ltd | Composition for inhibiting hyperlipidemia and obesity by inhibiting intestinal absorption of cholesterol |
US10377815B2 (en) | 2015-05-05 | 2019-08-13 | Albert Einstein College Of Medicine | Bispecific antibodies and fusion proteins that bind to EBOV and NPC1 |
Family Cites Families (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5688787A (en) * | 1991-07-23 | 1997-11-18 | Schering Corporation | Substituted β-lactam compounds useful as hypochlesterolemic agents and processes for the preparation thereof |
HUT67341A (en) * | 1991-07-23 | 1995-03-28 | Schering Corp | Substituted beta-lactam compounds useful as hypocholesterolemic agents, pharmaceutical compositions containing the same and process for the production thereof |
US5688785A (en) * | 1991-07-23 | 1997-11-18 | Schering Corporation | Substituted azetidinone compounds useful as hypocholesterolemic agents |
US5561227A (en) * | 1991-07-23 | 1996-10-01 | Schering Corporation | Process for the stereospecific synthesis of azetidinones |
LT3300B (en) * | 1992-12-23 | 1995-06-26 | Schering Corp | Combination of a cholesterol biosynhtesis inhibitor and a beta- lactam cholesterol absorbtion inhibitor |
LT3595B (en) * | 1993-01-21 | 1995-12-27 | Schering Corp | Spirocycloalkyl-substituted azetidinones useful as hypocholesterolemic agents |
NZ268798A (en) * | 1993-07-09 | 1997-01-29 | Schering Corp | Process for the preparation of substituted azetidinones |
US5631365A (en) * | 1993-09-21 | 1997-05-20 | Schering Corporation | Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents |
US5627176A (en) * | 1994-03-25 | 1997-05-06 | Schering Corporation | Substituted azetidinone compounds useful as hypocholesterolemic agents |
US5633246A (en) * | 1994-11-18 | 1997-05-27 | Schering Corporation | Sulfur-substituted azetidinone compounds useful as hypocholesterolemic agents |
US5624920A (en) * | 1994-11-18 | 1997-04-29 | Schering Corporation | Sulfur-substituted azetidinone compounds useful as hypocholesterolemic agents |
US5656624A (en) * | 1994-12-21 | 1997-08-12 | Schering Corporation | 4-[(heterocycloalkyl or heteroaromatic)-substituted phenyl]-2-azetidinones useful as hypolipidemic agents |
US5618707A (en) * | 1996-01-04 | 1997-04-08 | Schering Corporation | Stereoselective microbial reduction of 5-fluorophenyl-5-oxo-pentanoic acid and a phenyloxazolidinone condensation product thereof |
WO1997016424A1 (en) * | 1995-11-02 | 1997-05-09 | Schering Corporation | Process for preparing 1-(4-fluorophenyl)-3(r)-(3(s)-hydroxy-3-([phenyl or 4-fluorophenyl])-propyl)-4(s)-(4-hydroxyphenyl)-2-azetidinone |
US5886171A (en) * | 1996-05-31 | 1999-03-23 | Schering Corporation | 3-hydroxy gamma-lactone based enantioselective synthesis of azetidinones |
US5739321A (en) * | 1996-05-31 | 1998-04-14 | Schering Corporation | 3-hydroxy γ-lactone based enantionselective synthesis of azetidinones |
US5756470A (en) * | 1996-10-29 | 1998-05-26 | Schering Corporation | Sugar-substituted 2-azetidinones useful as hypocholesterolemic agents |
WO1999001555A1 (en) * | 1997-07-03 | 1999-01-14 | The United States Of America Represented By The Secretary, Department Of Health And Human Services | Genes for niemann-pick type c disease |
US6133001A (en) * | 1998-02-23 | 2000-10-17 | Schering Corporation | Stereoselective microbial reduction for the preparation of 1-(4-fluorophenyl)-3(R)-[3(S)-Hydroxy-3-(4-fluorophenyl)propyl)]-4(S)-(4 -hydroxyphenyl)-2-azetidinone |
US5919672A (en) * | 1998-10-02 | 1999-07-06 | Schering Corporation | Resolution of trans-2-(alkoxycarbonylethyl)-lactams useful in the synthesis of 1-(4-fluoro-phenyl)-3(R)- (S)-hydroxy-3-(4-fluorophenyl)-propyl!-4(S)-(4-hydroxyphenyl)-2-azetidinone |
WO2000034240A1 (en) | 1998-12-07 | 2000-06-15 | Schering Corporation | Process for the synthesis of azetidinones |
US6207822B1 (en) * | 1998-12-07 | 2001-03-27 | Schering Corporation | Process for the synthesis of azetidinones |
CN1249250C (en) | 1999-04-05 | 2006-04-05 | 先灵公司 | Stereoselective microbial reduction for prpn. of 1-(4-fluorophenyl)-3(R)-[3(s)-hydroxy-3-(4-fluorophenyl)propyl)-4(s)-(-4hydroxyphenyl)-2-azetidinone |
US6593078B1 (en) * | 1999-04-16 | 2003-07-15 | Schering Corporation | Use of azetidinone compounds |
WO2001057190A2 (en) | 2000-02-03 | 2001-08-09 | Hyseq, Inc. | Novel nucleic acids and polypeptides |
WO2001070974A1 (en) | 2000-03-24 | 2001-09-27 | Takeda Chemical Industries, Ltd. | Novel protein, process for producing the same and use thereof |
US6436703B1 (en) | 2000-03-31 | 2002-08-20 | Hyseq, Inc. | Nucleic acids and polypeptides |
NZ525921A (en) * | 2001-01-26 | 2005-06-24 | Schering Corp | Combinations of peroxisome proliferator-activated receptor (PPAR) activator(s) and sterol absorption inhibitor(s) and treatments for vascular indications |
AU2002258605B2 (en) | 2001-03-28 | 2006-01-12 | Merck Sharp & Dohme Corp. | Enantioselective synthesis of azetidinone intermediate compounds |
WO2003100094A2 (en) | 2002-05-23 | 2003-12-04 | Devgen Nv | Method for determining the influence of a compound on cholesterol transport |
US20040132058A1 (en) * | 2002-07-19 | 2004-07-08 | Schering Corporation | NPC1L1 (NPC3) and methods of use thereof |
US7135556B2 (en) * | 2002-07-19 | 2006-11-14 | Schering Corporation | NPC1L1 (NPC3) and methods of use thereof |
US20040093629A1 (en) * | 2002-07-19 | 2004-05-13 | Schering Corporation | NPC1L1 (NPC3) and methods of use thereof |
US20040137467A1 (en) * | 2002-07-19 | 2004-07-15 | Schering Corporation | NPC1L1 (NPC3) and methods of use thereof |
JP4575772B2 (en) | 2002-08-06 | 2010-11-04 | サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | Method for isolating intestinal cholesterol binding protein |
AU2003288925A1 (en) | 2002-10-08 | 2004-05-04 | Massachusetts Institute Of Technology | Compounds for modulation of cholesterol transport |
EP1723414A4 (en) | 2004-01-16 | 2008-03-26 | Merck & Co Inc | Npc1l1 (npc3) and methods of identifying ligands thereof |
EP1789437A4 (en) | 2004-07-30 | 2008-11-05 | Sinai School Medicine | Npc1l1 and npc1l1 inhibitors and methods of use thereof |
-
2005
- 2005-01-14 EP EP05711542A patent/EP1723414A4/en not_active Withdrawn
- 2005-01-14 CA CA2553769A patent/CA2553769C/en not_active Expired - Fee Related
- 2005-01-14 WO PCT/US2005/001469 patent/WO2005069900A2/en active Application Filing
- 2005-01-14 US US10/586,310 patent/US7901893B2/en not_active Expired - Fee Related
- 2005-01-14 MX MXPA06008124A patent/MXPA06008124A/en unknown
- 2005-01-14 JP JP2006549676A patent/JP4590417B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
JP2007526998A (en) | 2007-09-20 |
WO2005069900B1 (en) | 2006-08-03 |
CA2553769C (en) | 2011-01-04 |
MXPA06008124A (en) | 2007-01-26 |
WO2005069900A3 (en) | 2006-06-08 |
JP4590417B2 (en) | 2010-12-01 |
US7901893B2 (en) | 2011-03-08 |
US20100009461A1 (en) | 2010-01-14 |
EP1723414A2 (en) | 2006-11-22 |
EP1723414A4 (en) | 2008-03-26 |
WO2005069900A2 (en) | 2005-08-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2553769A1 (en) | Npc1l1 (npc3) and methods of identifying ligands thereof | |
JP2007526998A5 (en) | ||
WO2004074310A8 (en) | Mycobacterial diagnostics | |
WO2003012068A3 (en) | Novel fusion proteins and assays for molecular binding | |
WO2000078971A3 (en) | Atp binding cassette transporter protein abc1 popypeptides | |
GB0106953D0 (en) | Neufofibrillary labels | |
WO2004033631A8 (en) | Nucleic acid and polypeptide sequences from lawsonia intracellularis and methods of using | |
JP2008529537A5 (en) | ||
WO2001055303A3 (en) | Nucleic acids, proteins, and antibodies | |
WO2005087811A3 (en) | Estrogen receptors and methods of use | |
WO2004019000A3 (en) | Chemical reagents and methods for detection and quantification of proteins in complex mixtures | |
WO2009141384A3 (en) | Process for the purification of factor vii polypeptides using affinity resins comprising specific ligands | |
WO2006087163A3 (en) | Novel in vitro methods for studying receptors recognizing volatile compounds | |
JP2010528584A5 (en) | ||
JP2005538380A5 (en) | ||
WO2003029814A3 (en) | Neuropilin/vegf c/vegfr 3 materials and methods | |
Robinson et al. | Late‐Stage Functionalization by Chan–Lam Amination: Rapid Access to Potent and Selective Integrin Inhibitors | |
AU2023499A (en) | Pth receptor and screening assay utilizing the same | |
WO2001051669A3 (en) | Nucleic acid binding assay and selection method | |
DE69939275D1 (en) | Peptides consisting of two functional PTH domains linked by a linker molecule and derivatives thereof | |
WO2007051603A3 (en) | Kit comprising 2, 4- dichlorophenoxyacetic acd derivatives and antibodies for highly sensitive detection assays | |
WO2002026930A3 (en) | Nucleic acids, proteins, and antibodies | |
WO2001085930A3 (en) | Methods and compounds for modulating melanocortin receptor ligand binding and activity | |
WO2005047851A3 (en) | Device for measuring nanometer level pattern-dependent binding reactions | |
Sato et al. | Chemical Approaches Untangling Sequence‐Specific DNA Binding by Proteins |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
MKLA | Lapsed |
Effective date: 20150114 |